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Table 1
Differences in synovial ﬂuid biomarkers in acutely knee injured patients with or without at least one concomitant osteochondral fracture.
Median (25th-75th percentile) P-value; Adjusted for:
Fracture No fracture DBI DBI + age + sex DBI + age + sex + TOI
sGAG mg/ml SF 168.4 (77.6-305.6) 134.5 (75.6-331) 0.65 0.59 0.59
ARGS pmol/ml SF 72.9 (32.2-170.7) 59 (18.1-184.5) 0.42 0.47 0.48
OCL ng/ml SF 34.8 (22.8-50.8) 41.8 (25.7-55.7) 0.33 0.62 0.52
SPARC ng/ml SF 471.3 (322.0-767.0) 407 (139.9-684.9) 0 12 0.061 0.057
OPN ng/ml SF 74.6 (20-160.2) 29.1 (5.9-78.9) 0.11 0.11 0.11
IL 1b pg/ml SF 10.9 (4.4-29.6) 11.5 (4.9-27.8) 0.67 0.54 0.52
IL6 pg/ml SF 3386 (740-14425) 3602.3 (1254-14896) 0.95 1.0 0.99
IL8 pg/ml SF 211.4 (88.9-416.6) 137.5 (66.7-412.6) 0.22 0.22 0.22
TMFa pg/ml SF 9.2 (6.6-12.3) 6.9 (4.6-13.7) 0.036 0.013 0.012
COMP ng/ml SF 29885 (20814-36289) 27801 (20638-46503) 0.73 0.81 0.81
Between groups statistical testing was performed using ANCOVA on the log 10 transformed concentrations (adjusted statistics) The covariatcs; days between the injury and
synovial ﬂuid aspiration (DBI), age at injury, sex and type of injury (TOI: ACL, PCL, patellar dislocation, isolated meniscal tear/s or no signs of Structural intraarticular injury to
soft tissues) were included in the adjusted analysis. The tests were two-tailed with a P-value < 0.05 considered statistically signiﬁcant. Signiﬁcant differences are bolded. The
distribution of knee injuries as assessed by MRI between the two groups were as follows; Fracture/No fracture: ACL: 46/14; PCL: 1/1: patellar dislocation; 10/4, isolated
meniscal tear/s: 4/5; no signs of structural intra-articular injury to soft tissues: 6/7
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EXPLORATORY BIOMARKERANALYSIS REVEALS AGENETIC EPISTATIC
INTERACTION IN INTERLEUKIN 1 RECEPTOR ANTAGONIST (IL1RN)
GENE ASSOCIATED TO CARTILAGE VOLUME GROWTH MEASURED BY
MRI IN RESPONSE TO SPRIFERMIN THERAPY IN PATIENTS WITH
KNEE RADIOGRAPHIC OSTEOARTHRITIS
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Purpose: Osteoarthritis (OA) has recently been recognized as a hetero-
geneous disease with different underlying pathophysiologies, thus
opening new possibilities for personalized / stratiﬁed medicine. We
report an exploratory biomarker analysis performed within the context
of a phase 1 randomized, double blind, placebo-controlled, multicenter,
multiple ascending dose study involving sprifermin (recombinant
human FGF18) administered intra-articularly in patients with primary
knee OA.
Methods: Subjects participating in the “Multicenter Study of rhFGF18 in
Patients With Knee Osteoarthritis Not Requiring Surgery” Phase 1
clinical trial (previously presented, OARSI 2011) and consenting to the
pharmacogenomic study were included in this analysis. The trial was
designed as a randomized, double blind, placebo-controlled, multi-
center study. At baseline, all patients had Kellgren-Lawrence grade 2 or
3. All analyses were performed on the pharmacogenomic Intent-To-
Treat population, corresponding to a subset of the clinical database.
Biomarker analyses focused on the Multiple Ascending Dose cohort
(one injection per week for three weeks per subject; two treatment
cycles). The following treatment arms were available: 10 micrograms
(mcg) (with n¼21 subjects), 30 mcg (n¼34) or 100 mcg (n¼50) and
matched placebo subjects (n¼32). Subjects were followed-up for 52
weeks (trial termination date) with evaluation of their total cartilage
thickness/volume growth, measured by MRI, and WOMAC score
assessed at deﬁned time points. Both candidate (TaqMan) and whole-
genome (Affymetrix 6.0 arrays) SNP proﬁling of blood extracted DNA
from consenting subjects were performed. All SNPs were tested for
statistical association with change in total cartilage thickness / volume
at 52 weeks and WOMAC scores using linear models with Kellgren-
Lawrence grade, gender, age and BMI as adjustment covariables
Results: In the non-stratiﬁed PGx population, a median cartilage
volume growth increase of 146.93 mm3 (p ¼ 0.0157) relative to
placebo was observed in the sprifermin MAD 100 mcg arm. Biomarker
analyses identiﬁed a combination of SNPs, rs9005 and rs315952, both
located on the IL1RN gene that retrospectively identiﬁed a group of
patients where an 217.16 mm3 cartilage volume median increase over
placebo (p ¼ 0.0016) was observed. Furthermore, the cartilage volume
change in placebo subjects across the different genetic groups
suggests that this combination of SNP may also be indicative of
disease severity.Conclusions: These results illustrate how pharmacogenomics
approaches can generate exploratory hypotheses, which need to be
conﬁrmed in adequately designed upcoming clinical trials, and suggest
the potential to develop personalized pharmacologic treatment in OA
patients.126
SOLUBLE MACROPHAGE BIOMARKERS ARE ASSOCIATED WITH
OSTEOARTHRITIS-RELATED KNEE INFLAMMATION
H.N. Daghestani, G. McDaniel, J.L. Huebner, T. Stabler, C. Pieper,
E. Coleman, V.B. Kraus. Duke Univ., Durham, NC, USA
Purpose: Despite the prevalence, disability, and societal and personal
costs of osteoarthritis (OA), current treatment paradigms are limited to
palliative measures and ultimately joint replacement. One of the many
reasons purported for this lack of progress has been the slow evolution
of the understanding of the complex nature of joint tissue biology, and
the absence of biomarkers to identify disease subsets and monitor
efﬁcacy of interventions. A major recent advance in the understanding
of OA pathology has been the recognition of the role of innate immu-
nity. As part of a chronic maladaptive wound healing response in OA,
synovial macrophage-produced cytokines drive aggrecanases, matrix
metalloproteinases, and other destructive responses. We recently
discovered that the pattern of synovial ﬂuid cytokines in knee OA is
indicative of macrophage-mediated inﬂammasome activation. In a pilot
study of knee OA subjects, using a novel nuclear imaging methodology
known as FolateScan, we conﬁrmed the presence of activated macro-
phages in the majority of symptomatic osteoarthritic knees (66% posi-
tive; n¼25 patients, 50 knees). Activated macrophages in the synovium
and joint capsule were both strongly associated with joint space nar-
rowing, osteophyte severity, and knee symptoms. These data demon-
strate that macrophages play a critical role in OA symptoms and
progression. The goal of this study was to evaluate whether soluble
circulating macrophage-related markers, sCD14 and sCD163, were
associated with the presence of activated macrophages localized to the
knee and severity of radiographic knee OA.
Methods: sCD14 and sCD163 were measured by ELISA in the plasma
and sera, respectively of 25 subjects with knee OA. The severity of joint
space narrowing (JSN) and osteophyte (OST) were scored from ﬁxed
ﬂexion knee radiographs with the aid of a standard radiographic atlas.
FolateScan uptake was scored by an experienced reader (REC) on a 0-3
scale for the synovium and joint capsule from SPECT/CT knee scans.
Models using generalized estimating equations (to account for corre-
lation within knees), or ChiSquare analysis (for the biomarkers in
combination) were performed with adjustment for age, gender, and
body mass index, to evaluate associations of the biomarkers with
FolateScan results and radiographic OA features. P values 0.05 were
considered signiﬁcant.
Results: sCD14 and sCD163 were both signiﬁcantly associated with the
quantity of activated macrophages in knees. sCD14 was most strongly
associated with the presence of activatedmacrophages in the capsule of
the patellofemoral (PF) knee compartment (p¼0.0378); sCD163 was
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the tibiofemoral (TF) compartments (p¼0.0063) and the whole joint
synovium (p¼0.0017). sCD163 was also associated with severity of
radiographic OA, speciﬁcally joint space narrowing (p¼0.0554), but not
osteophyte severity. The use of the markers in combination improved
the prediction of activated macrophages in the capsule of the PF knee
compartment (p¼0.013) and joint space narrowing (p¼0.0099) inde-
pendent of osteophyte severity.
Conclusions: These ﬁndings suggest that cell-surface markers shed
from activated macrophages may be used as biomarkers to identify
a subtype of OA patients with an active inﬂammatory disease state. The
combined analysis of both CD14 and CD163 indicate synergism between
the markers for identifying the presence of activated macrophages in
the capsule of the PF knee and joint space narrowing. Furthermore,
these results contribute to a growing literature identifying macro-
phages and macrophage-activation pathways as potential targets for
new OA therapies.
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CHONDROCYTE HYPERTROPHY, MEASURED BY THE SECRETION OF
COLLAGEN TYPE X, IS A HALLMARK OF PATHOLOGICAL CHANGES
IN OSTEOARTHRITIS
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Purpose: Collagen type X (Col X) is a short chain and network-forming
collagen, which is speciﬁcally synthesized by hypertrophic chondrocyte
in the growth plate during endochondral ossiﬁcation, the calciﬁed
cartilage in normal adult or the deep zone of osteoarthritic (OA) carti-
lage; thus Col Xmay play an important role in cartilage calciﬁcation. The
aim of the study was to measure serum levels Col X in OA patients as
well characterize the presence of the ColX in OA cartilage section.
Methods:Amonoclonal antibody (mAb)was raised against the 10aa at C-
terminus of NC1 domain of Col X. ThismAbwas characterized bywestern
blot using U2-OS osteosarcoma cell as positive control, and by immuno-
histochemistry on 5 human OA knee cartilages sections. A solid-phase
competitive ELISAwas developed applying the mAb and tested in a small
cohort including: 47 OA patients undergoing total knee replacement
surgery (mean age  SD: 6415), and 13 controls with knee problems
having arthroscopy (mean age SD: 3421), all women. Mann-Whitney
test was applied to compare the serum Col X levels in TKR and control
group. Pearson correlationwas done on log transformed data.
Results: The mAb, NB509-11G8, was speciﬁc for the immunogen; it did
not recognize truncated or nonsense peptides when tested in the ELISA.
The mAb detected the monomeric Col X (59KDa) and dimeric Col X
(120KDa) in the U2-OS cell lysate. Moreover, these bands were blocked
by the speciﬁc peptide. NB509-11G8 stained the extracellular matrix of
chondrocytes in the deep zone and calciﬁed cartilage of human OA
samples but not the middle or upper zone (ﬁg. A). The competitive
ELISA had a measuring range of 0.02-5 ng/ml, with intra- and inter-
assay CVs of 4.19% and 10.62%. The mean serum Col X level was
signiﬁcantly higher in the TKR than the control group (P¼0.017, ﬁg. B).
Serum Col X level did not correlate with age (R2¼0.055), but weakĂrelationwith BMI (R2¼0.17). The AUC for serum Col X for discriminating
TKR from controls was 0.72 (P¼0.017).
Conclusions: Secretion of Col X as a marker of cartilage hypertrophy
may serve as an early biomarker for OA burden of disease.
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CTX-II IS A MARKER OF CARTILAGE DEGRADATION BUT NOT OF
BONE TURNOVER
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Purpose: The CTx-II biomarker has been widely investigated and used
to determine the status of cartilage turnover in osteoarthritis and
rheumatoid arthritis. Recent publications have discussed the possibility
that CTx-II release may partially reﬂect bone turnover rather than being
a speciﬁc marker of cartilage turnover. As CTx-II has been used so
widely, it is clear that the speciﬁcity of CTx-II for cartilage needed to be
re-evaluated. To this end, we decided to investigate the speciﬁcity of
CTx-II for cartilage in comparison to the gold standard CTx-I bone
degradation marker. We investigated the speciﬁcity of the ELISAs for
their respective epitopes, release of CTx-I and CTx-II from bone and
cartilage explant cultures, and levels of CTx-II and CTx-I in a small acute
injury and osteoarthritis (OA) cohort.
Methods: ELISA speciﬁcity for CTx-I and CTx-II was determined by
depletion of the epitopes from urine and by afﬁnity puriﬁcation of the
epitopes. Release of CTx-I and CTx-II from bone and cartilage was
investigated by digesting both cartilage and bone with either cathepsin
K or matrix metalloproteinases, and release of CTx-I and CTx-II deter-
mined by ELISA. We also investigated the release of CTx-I and CTx-II in
explant culture from both bone by osteoclasts mediated bone degra-
dation and from pro-inﬂammatory cytokine-stimulated cartilage
explant cultures. Finally, we investigated the changes in CTx-I and CTx-
II in patient cohorts.
Results: In vitro, cathepsin K digestion of bone released CTx-I alone
while digestion of bone with activated MMPs was unable to release
either CTx-I or CTx-II from bone. Only digestion of cartilage by activated
MMPs released CTx-II, while digestion of cartilage by either MMPs or
cathepsin K was unable to release detectable CTx-I. Osteoclast digestion
of bone slices released only CTx-I and no detectable CTx-II, while the
reverse was true in chondrocyte-mediated cartilage degradation, with
high CTx-II release and no detectable CTx-I. In our OA patient cohorts
we observed an increase in CTx-II levels when compared to healthy
controls but no change in CTx-I, while acute injury patients demon-
strated a reduction in CTx-I levels after injury and no change in CTx-II.
Conclusions: Our data strongly suggest that CTx-I reﬂects bone
degradation and CTx-II reﬂects cartilage degradation, and that in acute
injury and in osteoarthritis, bone turnover and cartilage degradation/
repair processes differ. As CTx-II reﬂects cartilage degradation, it is
a valid biomarker of cartilage breakdown and not a biomarker of bone
turnover, although in some cases it may reﬂect the connected pathology
of bone and cartilage in joint diseases.
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CTX-II LEVELS ARE ASSOCIATED WITH PERIPHERAL BONE DENSITY,
SUGGESTING CTX-II EPITOPE RELEASE FROM BONE: DATA FROM
COHORT HIP AND COHORT KNEE (CHECK)
W.E. van Spil, K.L. Vincken, W.F. Lems, F.P. Lafeber. Univ. Med. Ctr.
Utrecht, Utrecht, The Netherlands
Purpose: Recent data have suggested that CTX-II (C-terminal telopep-
tide of collagen type II) may not only originate from articular cartilage
but also from bone changes. Therefore, the purpose of this study was to
look for cross-sectional associations between urinary CTX-II levels and
bone density distant from the subchondral bone area.
Methods: This study was performed in 366 subjects with early-stage
symptomatic knee and/or hip osteoarthritis from Cohort Hip and
Cohort Knee (CHECK). In urine (u-) and serum (s-) samples from these
subjects, uCTX-II, the cartilage markers sCOMP, sPIIANP, and sCS846
(cartilage oligomeric matrix protein, N-terminal propeptide of pro-
collagen type IIA, and chondroitin sulphate 846), and the bone markers
uNTX-I, uCTX-I, sPINP, and sOC (N and C-terminal telopeptides of
collagen type I, N-terminal propeptide of procollagen type I, and
osteocalcin) were assessed by enzyme-linked immunosorbent assay or
radioactive immunoassay. Bone density was determined at the tibia and
